Nura Bio has completed a $73.8 million Series B financing round as it advances its pipeline of SARM1 inhibitors.  The financing, led by The Column Group, is set to fund the development of Nura Bio’s clinical pipeline, including the Phase Ib/IIa study of NB-4746, an oral, brain-penetrant SARM1 inhibitor.  NB-4746 has been shown to prevent axon […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!